What to Expect From Moderna’s Upcoming Earnings Call

Few companies have ever been catapulted into the consciousness of the masses as quickly as Moderna (NASDAQ: MRNA) was in the wake of the COVID-19 pandemic. The pharmaceutical firm quickly rose to a position as one of the most mentioned names in the business world on the back of its highly-contentious vaccine.

Now, with the world seemingly beginning to heal, we examine what to expect from Moderna’s hotly-anticipated Q4 earnings call later this week.

When is Moderna’s Q4 earnings date?

Moderna is set to report its Q4 and fiscal year 2021 earnings at 8 AM EST on Thursday, February 24, 2022.

How do I listen to Moderna’s earnings call?

Moderna’s earnings will be hosted via conference call and live webcast on the company’s investor relations page. A full replay of the webcast will also remain available afterward on the same page approximately two hours following the call.

What to expect from Moderna’s earnings

Analysts expect Moderna to post earnings per share (EPS) of $9.90 for the quarter, on revenue of $6.79 billion. This would see phenomenal growth on the year-ago quarter of 1535% and 1090% respectively. Tremendous growth is to be expected considering how widespread the company’s COVID vaccine is and, as such, investors are unlikely to be bowled over by these huge numbers. Instead, they will be looking to the company’s future.

Moderna stock has been on a steady decline since beyond the beginning of the year, and that slide looks set to be exacerbated by the increasingly accepted view that the worst of the pandemic is over. With the COVID vaccine currently Moderna’s only commercialized product, investors will need evidence that the company has a plan to continue growing as the world gets back to normal.

The inevitable rising competition also becomes a factor as more companies become involved in the space as our knowledge of COVID continues to develop. Investors will be eager to hear what guidance the company offers on how it hopes to handle coronavirus treatments moving forward. 

Targeted booster shots will be one avenue to be explored, while the company also has plans to develop an annual combination booster that will protect against a whole host of viruses. The development of a program such as this could provide Moderna with a fantastic source of yearly recurring revenue. However, competition such as Novavax are already winning the race to develop such a vaccine, so time is of the essence. 

Investors will also be looking for more news in relation to the recent insider sell-off of Moderna stock. Four executives from the company — including CEO Stéphane Bancel — sold over 23,000 shares last week equating to roughly $3.6 million. Bancel still retains an 8% ownership of the company, but investors will still require reassurance that all remains well internally at Moderna.